Colchicine is indicated for the treatment of acute gout. It is best initiated within 24 hours of an acute attack of gout because early treatment leads to better patient-reported outcomes. If the response to colchicine is considered inadequate, try other options as monotherapy such as NSAIDs (non-steroidal anti-inflammatory drugs) or corticosteroids.

Colchicine inhibits the inflammatory response to urate crystals that cause pain and inflammation during an attack of gout. Colchicine also helps to reduce the incidence of acute attacks and relieve residual pain following an attack. This is especially useful while urate-lowering medicines, such as allopurinol, are being initiated. Colchicine alone will not prevent the progression of gout to chronic gouty arthritis.

Make sure patients understand that they should continue their established urate-lowering medicines (eg allopurinol or febuxostat) without interruption during an acute attack of gout.

CONSIDER RENAL FUNCTION AND INTERACTIONS WITH OTHER MEDICINES

Lower doses of colchicine are recommended for the elderly, for patients with hepatic or renal impairment, and for patients who weigh less than 50kg. Colchicine is contraindicated in severe renal or hepatic disease.

The elderly are particularly sensitive to cumulative toxicity with colchicine due to age-related renal impairment. If colchicine is required, prescribe half the recommended dose (see Table 1) and ensure they are aware of the signs of toxicity. Acute renal failure has occurred in elderly patients taking colchicine who are dehydrated following episodes of diarrhoea and vomiting.

Table 1: Colchicine dose recommendations for acute gout attacks

<table>
<thead>
<tr>
<th>Renal function (eGFR)</th>
<th>Initial Dose*</th>
<th>Continuing Dose*</th>
<th>Maximum Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over 50mL/min/1.73m²</td>
<td>1mg (2 tablets)</td>
<td>0.5mg (1 tablet) every 12-24h</td>
<td>Then if needed, after 12 hours, up to 0.5mg three times daily until the acute attack resolves. (Total maximum 2mg colchicine per day)</td>
</tr>
<tr>
<td>10-50mL/min/1.73m²</td>
<td>0.5mg (1 tablet)</td>
<td>0.5mg (1 tablet) every 12-24h</td>
<td>1mg (2 tablets) in first 24 hours 3mg (6 tablets) over 4 days</td>
</tr>
<tr>
<td>Under 10mL/min/1.73m²</td>
<td>Avoid</td>
<td>Avoid</td>
<td>Avoid</td>
</tr>
</tbody>
</table>

*Stop when relief obtained or at the first sign of toxicity

All patients should be encouraged to use the lowest effective dose of colchicine because toxicity is dose-related. Low-dose colchicine (2 tablets initially, followed by 1 tablet an hour later) compared with high-dose colchicine (2 tablets initially, followed by 1 tablet every hour for 6 hours) in the first 24 hours of acute gout provides no loss of efficacy, but a significant reduction in adverse effects.
The total dose of colchicine should not exceed 6mg over 4 days. In high-risk groups (elderly patients and those with renal impairment), the maximum dose in the first 24 hours should not exceed 1mg and the total dose of colchicine should not exceed 3mg over four days.

It is important that there is a gap of at least 3 days between courses of acute treatment to avoid toxicity from colchicine accumulation.

**Colchicine prophylaxis**

Colchicine prophylaxis therapy (0.5mg daily or twice daily) may be commenced the day following treatment for an acute attack. At this dose, colchicine is effective at preventing flares of gout when patients start urate-lowering medicines (eg allopurinol or febuxostat). It is important that patients are aware of this, and continue to take colchicine prophylaxis for 3-6 months after they achieve target serum urate with their urate-lowering medicines.

**Notable interactions**

Colchicine is contraindicated if patients have renal or hepatic impairment and they are taking other medicines that increase the risk of colchicine toxicity. These medicines include macrolides (eg erythromycin, clarithromycin), imidazoles (eg fluconazole, ketoconazole, itraconazole), protease inhibitors (eg ritonavir), diltiazem, verapamil, and ciclosporin.

Patients who are taking these medicines without renal or hepatic impairment may take colchicine at a reduced dose. See the New Zealand Formulary www.nzf.org.nz for a comprehensive list.

Patients who are taking statins or fibrates in combination with colchicine, should be advised to promptly report any unexplained muscle pain or weakness; there have been some case reports of rhabdomyolysis and myopathy.

**ENSURE PATIENTS UNDERSTAND THE RISKS ASSOCIATED WITH COLCHICINE**

During an acute attack, patients are likely to start treatment with colchicine by themselves at home. Appropriate patient education is important given the narrow therapeutic range of colchicine. Patients are at risk of toxicity if they have a poor understanding of how to take colchicine, the possible side-effects, and consequences of overdose.

A report of nine cases of colchicine overdose in the Auckland region showed that 3 of the 4 accidental poisonings occurred in Pacific Island men. Even allowing for increased prevalence of gout in these groups, this suggests that a special effort is needed when colchicine is prescribed for these patients, especially if English is not their first language.

Patients should stop colchicine, and see their doctor if they develop:

- abdominal pain
- diarrhoea, nausea, vomiting
- burning sensation of the throat, stomach or skin

Ask the patient to take note of the dose taken so they know to use lower doses during subsequent attacks of gout.

In some circumstances, toxic effects may not appear until 24 hours after ingestion of an acute dose. If toxicity is suspected, prompt admission to a hospital with intensive care facilities is essential. There is no antidote; charcoal may be considered but treatment is generally supportive.

Remind patients to keep all medicines well out of reach and out of sight of children and grandchildren. Children are very vulnerable to colchicine poisoning; doses as small as 1 or 2 tablets can cause serious toxicity.
ACKNOWLEDGEMENTS

We wish to thank Nicola Dalbeth, Rheumatologist and Professor, Department of Medicine, University of Auckland and Peter Gow, Associate Professor of Rheumatology, Middlemore Hospital, for their valuable contribution to this bulletin.

REFERENCES


